Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A in Buerger’s disease
2024-517772-38-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in Buerger disease (TAO), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Feasibility of planned injections. Planned start Oct 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Buerger disease (TAO)
Beyond the preview
Go deeper on 2024-517772-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517772-38-00.